The IP3R-II activators comprise a diverse set of compounds that directly or indirectly influence the activity of IP3R-II, a critical player in intracellular calcium signaling. Notably, substances like 2-APB and Xestospongin C act as IP3 receptor antagonists, with 2-APB inhibiting IP3 binding and Xestospongin C specifically targeting IP3R-II. These compounds modulate the release of calcium from intracellular stores, impacting cellular processes regulated by intracellular calcium signaling. On the other hand, compounds such as 8-Bromo-cADPR and Ruthenium Red showcase indirect modulation of IP3R-II. 8-Bromo-cADPR enhances the sensitivity of IP3R-II to IP3, leading to increased calcium release. In contrast, Ruthenium Red, a non-specific IP3 receptor inhibitor, blocks calcium release from intracellular stores. These compounds collectively highlight the intricate regulatory mechanisms involved in IP3R-II activation and its role in calcium signaling. Additionally, modulators like U73122 and Carbachol influence IP3R-II indirectly through pathways involving phospholipase C (PLC) activation. U73122 inhibits PLC, reducing IP3 levels and subsequently affecting IP3R-II activation. Carbachol, through muscarinic acetylcholine receptor activation, triggers PLC-mediated IP3 production, leading to altered calcium release from intracellular stores.
Other compounds like ATP and Miconazole showcase the influence of purinergic receptors and inositol monophosphatase inhibition, respectively, on IP3R-II activity. ATP, through purinergic receptors, activates PLC and increases IP3 production, ultimately affecting IP3R-II activation. Miconazole, by blocking inositol monophosphatase, reduces IP3 availability, impacting IP3R-II activation and calcium release. BAPTA-AM and Procaine, as calcium chelator and PLC inhibitor, respectively, directly or indirectly modulate IP3R-II activity. BAPTA-AM sequesters intracellular calcium, altering IP3R-II activation and downstream signaling. Procaine, through PLC inhibition, decreases IP3 levels, influencing IP3R-II activity and calcium release.
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
8-Bromo-cADP-Ribose (8-Br-cADPR) | 151898-26-9 | sc-201514 sc-201514B | 100 µg 1 mg | ¥1467.00 ¥6206.00 | 12 | |
8-Bromo-cADPR 通过增强 IP3R-II 对 IP3 的敏感性而成为 IP3R-II 的调节剂。它增强了 IP3 与 IP3R-II 之间的相互作用,从而增加了内质网的钙释放。这会影响由细胞内钙信号调节的细胞过程。 | ||||||
Ruthenium red | 11103-72-3 | sc-202328 sc-202328A | 500 mg 1 g | ¥2076.00 ¥2764.00 | 13 | |
钌红是 IP3 受体(包括 IP3R-II)的非特异性抑制剂。通过与 IP3R-II 结合,它能阻止细胞内储存的钙释放,从而影响受细胞内钙信号调控的细胞过程。钌红具有抑制 IP3R-II 活性的作用。 | ||||||
Carbachol | 51-83-2 | sc-202092 sc-202092A sc-202092C sc-202092D sc-202092B sc-202092E | 1 g 10 g 25 g 50 g 100 g 250 g | ¥1354.00 ¥3103.00 ¥4287.00 ¥7559.00 ¥15795.00 ¥33846.00 | 12 | |
卡巴胆碱通过激活毒蕈碱乙酰胆碱受体间接影响 IP3R-II。下游信号级联涉及 PLC 激活,导致 IP3 生成增加。这反过来又增强了 IP3R-II 的激活,导致细胞内储存的钙释放增加,并调节由钙信号调节的细胞过程。 | ||||||
ATP | 56-65-5 | sc-507511 | 5 g | ¥192.00 | ||
腺苷-5'-三磷酸二钠盐通过嘌呤能受体间接调节 IP3R-II。ATP 与嘌呤能受体结合会激活 PLC,导致 IP3 生成增加。随后,IP3R-II 被激活,导致细胞内储存的钙释放增加,并影响受细胞内钙信号调控的细胞过程。 | ||||||
Miconazole | 22916-47-8 | sc-204806 sc-204806A | 1 g 5 g | ¥733.00 ¥1771.00 | 2 | |
咪康唑通过抑制肌醇单磷酸酶间接影响 IP3R-II。通过阻断肌醇单磷酸酶,咪康唑减少了产生 IP3 所需的肌醇。这导致 IP3 水平下降,进而影响 IP3R-II 的激活,并调节由细胞内钙信号调控的细胞过程。 | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | ¥1557.00 ¥5066.00 | 61 | |
BAPTA-AM 是一种膜渗透性钙螯合剂。通过螯合细胞内的钙,它可以间接调节 IP3R-II 的活性。细胞内钙水平的降低会影响 IP3R-II 的激活,从而导致受细胞内钙信号调控的细胞过程发生变化。 | ||||||
Procaine | 59-46-1 | sc-296134 sc-296134A sc-296134B sc-296134C | 25 g 50 g 500 g 1 kg | ¥1218.00 ¥2132.00 ¥4502.00 ¥6950.00 | 1 | |
普鲁卡因通过抑制 IP3 的产生间接调节 IP3R-II。通过抑制 PLC,它减少了 IP3 的合成,从而降低了 IP3R-II 的激活。这导致细胞内储存的钙释放减少,从而影响受细胞内钙信号调控的细胞过程。 |